Clinical effect of combined bevacizumab, pemetrexed and cisplatin on advanced non-small cell lung cancer

Objective To compare the clinical effect of combined pemetrexed and cisplatin, and bevacizumab alone on advanced nonsmall cell lung cancer (NSCLC). Methods Thirty-two advanced NSCLC patients who were treated with combined bevacizumab, pemetrexed and cisplatin (Avastin +PP) in our hospital from September 2009 to June 2013 served as an experimental group and 35 advanced NSCLC patients who were treated with combined pemetrexed and cisplatin(PP) served as a control group in this study. Patients in control group were treated with intravenous pemetrexed (500 mg/m²) on day 1 and cisplatin (75 mg/m²) on day 1 or on days 1-3, 21 days as a cycle. Those in experimental group were treated with intravenous bevaoizumab (7.5 mg/kg) on day 1, pemetrexed (500 mg/m²) on day 1 and cisplatin (75 mg/m²) on day 1 or on days 1-3, 21 days as a cycle. Results The disease control rate (DCR)and overall response rate (ORR) in the two groups were 90.6% and 60.0%, 56.9% and 25.7%, respectively (P< 0.05). The median progression-free survival (mPFS) time and median overall survival time (mOS) in the two groups were 7.3 months and 4.2 months, 20.7 months and 9.0 months, respectively (P< 0.05). No significant difference was found in adverse reaction between the two groups (P> 0.05) although bone marrow suppression, nausea, vomiting, hepatic and renal function damage occured. Conclusion The long-term and short-term effects of combined bevacizumab, pemetrexed and cisplatin are better than combined pemetrexed and cisplatin on advanced NSCLC with no severe adverse reaction.